Terms: = Breast cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Treatment
43 results:
1. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
Wu J; Wang W; Gao L; Shao X; Wang X
Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
[TBL] [Abstract] [Full Text] [Related]
2. dnmt3a Cooperates with YAP/TAZ to Drive Gallbladder cancer Metastasis.
Xu S; Yuan Z; Jiang C; Chen W; Li Q; Chen T
Adv Sci (Weinh); 2024 Apr; 11(16):e2308531. PubMed ID: 38380551
[TBL] [Abstract] [Full Text] [Related]
3. Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Bagheri M; Lee MK; Muller KE; Miller TW; Pattabiraman DR; Christensen BC
Epigenomics; 2024 Mar; 16(5):293-308. PubMed ID: 38356412
[No Abstract] [Full Text] [Related]
4. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study.
Toda S; Iwasaki H; Okubo Y; Hayashi H; Kadoya M; Takahashi H; Yokose T; Hiroshima Y; Masudo K
Endocr J; 2024 Jan; 71(1):31-37. PubMed ID: 38044137
[TBL] [Abstract] [Full Text] [Related]
5. Exploring Derivatives of Quinolizidine Alkaloid Sophoridine in the Design and Biological Mechanistic Evaluation of Histone Deacetylase Inhibitors against Triple-Negative breast cancer.
Dai L; Tan C; Wang H; Wang L; Zhang T; Zhi S; Yang Z; Zhao X; Li D
ChemMedChem; 2024 Jan; 19(2):e202300467. PubMed ID: 38031642
[TBL] [Abstract] [Full Text] [Related]
6. Oncolytic Activity of Canine Distemper Virus in Human Ductal breast Carcinoma Cells.
Jhala D; Nathani N; Joshi M; Patel A; Joshi CG
Oncol Res Treat; 2024; 47(1-2):10-17. PubMed ID: 38008084
[TBL] [Abstract] [Full Text] [Related]
7. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
8. Maternal exposure to bisphenol A induces fetal growth restriction via upregulating the expression of estrogen receptors.
Cao Y; Chen Z; Zhang M; Shi L; Qin S; Lv D; Li D; Ma L; Zhang Y
Chemosphere; 2022 Jan; 287(Pt 3):132244. PubMed ID: 34537452
[TBL] [Abstract] [Full Text] [Related]
9. Sesamol Epigenetically Induces Estrogen Receptor α Re-expression by Upregulating miR-370-3p in Estrogen Receptor α-Negative breast cancer.
Ma X; Wang J; Hu G; Chen Y; Hu X; Zhu Y; Ding L; Ning S
J Agric Food Chem; 2021 Aug; 69(31):8737-8746. PubMed ID: 34325508
[TBL] [Abstract] [Full Text] [Related]
10. TET2 and dnmt3a mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract] [Full Text] [Related]
11. LINC00922 regulates epithelial-mesenchymal transition, invasive and migratory capacities in breast cancer through promoting NKD2 methylation.
Wang Y; Dong T; Wang P; Li S; Wu G; Zhou J; Wang Z
Cell Signal; 2021 Jan; 77():109808. PubMed ID: 33045317
[TBL] [Abstract] [Full Text] [Related]
12. Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Liang F; Zhang H; Gao H; Cheng D; Zhang N; Du J; Yue J; Du P; Zhao B; Yin L
Exp Biol Med (Maywood); 2021 Feb; 246(4):459-466. PubMed ID: 32938226
[TBL] [Abstract] [Full Text] [Related]
13. Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors.
Hegde M; Guruprasad KP; Ramachandra L; Satyamoorthy K; Joshi MB
J Biol Chem; 2020 Aug; 295(34):12086-12098. PubMed ID: 32636303
[TBL] [Abstract] [Full Text] [Related]
14. Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway.
Li D; Hu X; Yu S; Deng S; Yan M; Sun F; Song J; Tang L
Cell Signal; 2020 Sep; 73():109697. PubMed ID: 32593652
[TBL] [Abstract] [Full Text] [Related]
15. dnmt3a mediates paclitaxel-induced abnormal expression of LINE-1 by increasing the intragenic methylation.
Wang XY; Zhang Y; Yang N; Cheng H; Sun YJ
Yi Chuan; 2020 Jan; 42(1):100-111. PubMed ID: 31956100
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of dnmt3a alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.
Zwergel C; Schnekenburger M; Sarno F; Battistelli C; Manara MC; Stazi G; Mazzone R; Fioravanti R; Gros C; Ausseil F; Florean C; Nebbioso A; Strippoli R; Ushijima T; Scotlandi K; Tripodi M; Arimondo PB; Altucci L; Diederich M; Mai A; Valente S
Clin Epigenetics; 2019 May; 11(1):68. PubMed ID: 31060628
[TBL] [Abstract] [Full Text] [Related]
18. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
Jahangiri R; Jamialahmadi K; Gharib M; Emami Razavi A; Mosaffa F
Gene; 2019 Feb; 685():24-31. PubMed ID: 30359738
[TBL] [Abstract] [Full Text] [Related]
19. Derivative of Stevioside; CPUK02; Restores ESR1 Gene Methylation in MDA-MB 231.
Khazayel S; Mokarram P; Mohammadi Z; Ramezani F; Dayong Z
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2117-2123. PubMed ID: 30139210
[TBL] [Abstract] [Full Text] [Related]
20. Linc01638 Promotes Tumorigenesis in HER2+ breast cancer.
Liu P; Tang H; Wu J; Qiu X; Kong Y; Zhang L; Xie X; Xiao X
Curr Cancer Drug Targets; 2019; 19(1):74-80. PubMed ID: 29992881
[TBL] [Abstract] [Full Text] [Related]
[Next]
